HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma

Abstract Background Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect the efficacy of TKI + IO. Metho...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Xianglai Xu, Sihong Zhang, Ying Wang, Yanjun Zhu, Jiajun Wang, Jianming Guo
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wiley 2023-05-01
סדרה:	Cancer Medicine
נושאים:	heme oxygenase 1 immune checkpoint inhibitor renal cell carcinoma T‐cell dysfunction tyrosine kinase inhibitor
גישה מקוונת:	https://doi.org/10.1002/cam4.5787
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!